Pliant Therapeutics Inc. (PLRX): Price and Financial Metrics
PLRX Price/Volume Stats
| Current price | $12.08 | 52-week high | $30.85 |
| Prev. close | $12.19 | 52-week low | $12.00 |
| Day low | $12.01 | Volume | 122,379 |
| Day high | $12.34 | Avg. volume | 383,930 |
| 50-day MA | $15.17 | Dividend yield | N/A |
| 200-day MA | $16.15 | Market Cap | 727.69M |
PLRX Stock Price Chart Interactive Chart >
Pliant Therapeutics Inc. (PLRX) Company Bio
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Latest PLRX News From Around the Web
Below are the latest news stories about PLIANT THERAPEUTICS INC that investors may wish to consider to help them evaluate PLRX as an investment opportunity.
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing CholangitisINTEGRIS-PSC interim results highlighted in an oral late-breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of preclinical data and clinical data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (P |
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsPositive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification Key Clinical Development and Regulatory appointments expand leadership team SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treat |
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?Pliant Therapeutics (PLRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Pliant Therapeutics to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following November investor conferences. Stifel 2023 Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will |
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleasePliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
PLRX Price Returns
| 1-mo | -18.93% |
| 3-mo | -27.66% |
| 6-mo | -11.50% |
| 1-year | -58.59% |
| 3-year | -57.13% |
| 5-year | N/A |
| YTD | -33.30% |
| 2023 | -6.31% |
| 2022 | 43.19% |
| 2021 | -40.58% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...